2 results
Approved WMOWill not start
Part BPrimary:• To determine the anti-tumor activity of NM21 1480 according to RECIST 1.1• To assess the safety and tolerability of NM21 1480 in patients with selected advanced cancers treated at or around the recommended Phase 2 dose (RP2D)• To…
Approved WMOPending
Part 1PrimaryTo assess dose limiting toxicities (DLTs) of EDR to select an RP3D for the combination to be used in Part 2 of this study.Secondary• To evaluate the overall safety profile of EDR to select an RP3D for the combination to be used in Part…